{"hands_on_practices": [{"introduction": "Understanding apoptosis requires not only knowing the components but also discerning how they are wired together in different cellular contexts. This exercise challenges you to think like an experimental biologist by designing a strategy to distinguish between Type I and Type II extrinsic apoptosis pathways. By logically applying perturbations using a caspase-8 inhibitor and B-cell lymphoma 2 (Bcl-2) overexpression, you will develop a critical understanding of how pathway architecture dictates sensitivity to molecular interventions [@problem_id:2932745].", "problem": "A researcher is tasked with determining whether a human carcinoma cell line undergoes extrinsic apoptosis as type I (receptor-dominant) or type II (mitochondria-amplified) when stimulated through death receptors by a ligand such as Fas ligand or Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL). The researcher is allowed only two perturbations: transient overexpression of B-cell lymphoma 2 (Bcl-2) and pharmacological inhibition of caspase-8. The readouts available are initiator caspase-8 activity, executioner caspase-3 cleavage/activity, mitochondrial outer membrane permeabilization (MOMP; assessed by cytochrome c release), and fraction of apoptotic cells by Annexin V staining. The researcher can use a $2 \\times 2$ experimental design (vector versus Bcl-2 overexpression) by ($\\pm$ caspase-8 inhibitor), and apply a fixed, receptor-saturating dose of ligand for 6 to 8 hours.\n\nUse the following foundational facts:\n- Extrinsic apoptosis is initiated by death receptor activation, formation of the Death-Inducing Signaling Complex (DISC), and activation of caspase-8; executioner caspases such as caspase-3 then mediate proteolysis associated with apoptosis.\n- In type I cells, robust DISC formation yields sufficient active caspase-8 to directly activate executioner caspases without requiring mitochondrial amplification.\n- In type II cells, DISC-derived caspase-8 activity is insufficient to directly activate executioner caspases; instead, caspase-8 must cleave BH3-interacting domain death agonist (Bid) to truncated Bid (tBid), which induces MOMP. MOMP releases cytochrome c to promote apoptosome assembly and caspase-9 activation, amplifying the caspase cascade.\n- Anti-apoptotic Bcl-2 localizes to mitochondria and blocks MOMP by neutralizing pro-apoptotic Bcl-2 family proteins; Bcl-2 does not inhibit DISC formation or caspase-8 activation.\n- A selective caspase-8 inhibitor blocks events downstream of DISC that require caspase-8 catalytic activity, including Bid cleavage, in both type I and type II contexts.\n\nWhich option best specifies an experimental strategy and decision rule that will discriminate type I from type II extrinsic apoptosis under these constraints while relying only on the stated foundational facts?\n\nA. Perform a $2 \\times 2$ matrix: vector control $\\pm$ caspase-8 inhibitor and Bcl-2 overexpression $\\pm$ caspase-8 inhibitor. After TRAIL stimulation for $6$ hours, quantify caspase-3 activity, Annexin V positivity, and cytochrome c release. Decision rule: If Bcl-2 overexpression significantly suppresses MOMP and reduces caspase-3 activation and apoptosis (for example, by $\\geq 50\\%$, with $p<0.05$) while caspase-8 inhibition abolishes apoptosis in both vector and Bcl-2 cells, classify as type II. If Bcl-2 overexpression reduces MOMP but does not significantly reduce caspase-3 activation or apoptosis, yet caspase-8 inhibition abolishes apoptosis, classify as type I.\n\nB. Treat vector-only cells with a caspase-8 inhibitor at a submaximal ligand dose and classify as type I if the inhibitor produces near-complete blockade of apoptosis (for example, $\\geq 80\\%$ reduction) and as type II if the inhibitor produces only partial blockade (for example, $\\leq 40\\%$ reduction), because type II apoptosis is less dependent on caspase-8.\n\nC. Overexpress Bcl-2 and measure caspase-8 enzymatic activity at $2$ hours post-stimulation. If Bcl-2 reduces caspase-8 activity by $\\geq 50\\%$, classify as type II, because Bcl-2 is upstream of caspase-8 in type II cells but not in type I cells.\n\nD. Perform the $2 \\times 2$ matrix with vector/Bcl-2 and $\\pm$ caspase-8 inhibitor, but use only caspase-3 activity as the readout. Decision rule: Classify as type I only if caspase-8 inhibition fails to block caspase-3 activation in Bcl-2 overexpressing cells, because type I cells have caspase-8-independent executioner activation, and as type II if caspase-8 inhibition blocks caspase-3 in both vector and Bcl-2 cells.", "solution": "The problem statement will first be subjected to rigorous validation.\n\n### Step 1: Extract Givens\n- **Task**: Determine if a human carcinoma cell line undergoes extrinsic apoptosis as type I or type II.\n- **Stimulus**: A fixed, receptor-saturating dose of a death receptor ligand (e.g., Fas ligand or TRAIL) for 6 to 8 hours.\n- **Allowed Perturbations**:\n    1.  Transient overexpression of B-cell lymphoma 2 (Bcl-2).\n    2.  Pharmacological inhibition of caspase-8.\n- **Experimental Design**: $2 \\times 2$ matrix (vector versus Bcl-2 overexpression) by ($\\pm$ caspase-8 inhibitor).\n- **Available Readouts**:\n    1.  Initiator caspase-8 activity.\n    2.  Executioner caspase-3 cleavage/activity.\n    3.  Mitochondrial outer membrane permeabilization (MOMP), assessed by cytochrome c release.\n    4.  Fraction of apoptotic cells by Annexin V staining.\n- **Foundational Facts**:\n    1.  Extrinsic apoptosis is initiated by death receptor activation, formation of the Death-Inducing Signaling Complex (DISC), and activation of caspase-8. Executioner caspases like caspase-3 mediate apoptosis.\n    2.  In type I cells, robust DISC formation yields sufficient active caspase-8 to directly activate executioner caspases without mitochondrial amplification.\n    3.  In type II cells, DISC-derived caspase-8 activity is insufficient. Caspase-8 must cleave BH3-interacting domain death agonist (Bid) to truncated Bid (tBid), which induces MOMP. MOMP releases cytochrome c, leading to caspase-9 activation and amplification of the caspase cascade.\n    4.  Anti-apoptotic Bcl-2 localizes to mitochondria and blocks MOMP. Bcl-2 does not inhibit DISC formation or caspase-8 activation.\n    5.  A selective caspase-8 inhibitor blocks events downstream of DISC that require caspase-8 catalytic activity, including Bid cleavage.\n\n### Step 2: Validate Using Extracted Givens\nThe problem statement is evaluated based on the established criteria.\n\n-   **Scientifically Grounded**: The problem is based on the well-established and canonical pathways of extrinsic apoptosis. The roles of caspase-8, caspase-3, Bcl-2, MOMP, and cytochrome c are described in accordance with standard molecular and cell biology literature. The distinction between type I and type II pathways is a fundamental concept in apoptosis research. The problem is free of scientific error or pseudoscience.\n-   **Well-Posed**: The problem sets a clear objective (discriminate type I vs. type II), provides a specific set of tools (perturbations and readouts), and defines the system (a cell line stimulated with a ligand). This structure allows for a unique, logical solution to be derived from the provided facts.\n-   **Objective**: The language is technical, precise, and devoid of subjective or ambiguous terminology.\n-   **Completeness and Consistency**: The problem provides all necessary information. The foundational facts are self-consistent and sufficient to construct a logical experimental strategy. There are no contradictions.\n-   **Realism**: The experimental design ($2 \\times 2$ matrix with overexpression and inhibitors), the perturbations, and the readouts (caspase assays, Annexin V, cytochrome c release) are all standard, feasible techniques in a cell biology laboratory.\n\n### Step 3: Verdict and Action\nThe problem statement is scientifically sound, well-posed, objective, and internally consistent. It represents a valid and standard conceptual problem in experimental biology. Therefore, a solution will be derived.\n\n### Principle-Based Derivation\nThe core task is to distinguish between two pathways originating from the same initial signal (death receptor activation) but diverging in their downstream amplification mechanisms. The logical approach is to perturb the system at a point where the two pathways differ.\n\n1.  **Shared Upstream Events**: Both type I and type II pathways are initiated by the activation of caspase-8 at the DISC. Consequently, inhibiting caspase-8 must block apoptosis in both cell types. This provides a critical control: if the caspase-8 inhibitor does not abrogate apoptosis, the observed cell death is not classical extrinsic apoptosis, and the premises of the experiment are violated.\n\n2.  **Divergent Amplification**: The key difference lies in the dependency on the mitochondrial pathway.\n    -   **Type I cells**: caspase-8 activity is high enough to directly activate executioner caspase-3, bypassing the need for mitochondrial involvement.\n    -   **Type II cells**: caspase-8 activity is low and requires an amplification loop through the mitochondria. Caspase-8 cleaves Bid to tBid, which triggers MOMP. This is the crucial amplification step.\n\n3.  **Targeting the Divergence Point**: The protein Bcl-2 is an inhibitor of MOMP. According to the provided facts, Bcl-2 acts at the mitochondria and does not affect upstream caspase-8 activation. This makes Bcl-2 the ideal tool to probe the dependency on the mitochondrial loop.\n    -   In **Type I cells**, where apoptosis proceeds without requiring MOMP, overexpression of Bcl-2 should have little to no effect on the final apoptotic outcome (e.g., caspase-3 activation, Annexin V positivity).\n    -   In **Type II cells**, where apoptosis is critically dependent on MOMP for signal amplification, overexpression of Bcl-2 will block this step, leading to a significant reduction or complete inhibition of apoptosis.\n\n4.  **Optimal Experimental Strategy**: A $2 \\times 2$ experimental design is appropriate. The conditions are:\n    i.  Vector control cells + Ligand: Establishes the baseline apoptotic response.\n    ii. Vector control cells + Ligand + caspase-8 inhibitor: Confirms that apoptosis is caspase-8-dependent. Apoptosis should be blocked.\n    iii. Bcl-2 overexpressing cells + Ligand: This is the discriminatory condition. Comparison of apoptosis levels with condition (i) reveals the cell type.\n    iv. Bcl-2 overexpressing cells + Ligand + caspase-8 inhibitor: Serves as an additional control. Apoptosis should be blocked, as in condition (ii).\n\n    **Decision Rule**: After stimulating all four conditions with the ligand, measure apoptotic readouts.\n    -   If apoptosis in condition (iii) is not significantly reduced compared to condition (i), the cells are **type I**.\n    -   If apoptosis in condition (iii) is significantly reduced compared to condition (i), the cells are **type II**.\n    In both cases, apoptosis must be nearly abolished in conditions (ii) and (iv). The readouts (caspase-3 activity, Annexin V, cytochrome c release) are all valid measures of the apoptotic process and its intermediate steps. Measuring multiple readouts provides a more robust conclusion.\n\n### Option-by-Option Analysis\n\n**A. Perform a $2 \\times 2$ matrix: vector control $\\pm$ caspase-8 inhibitor and Bcl-2 overexpression $\\pm$ caspase-8 inhibitor. After TRAIL stimulation for $6$ hours, quantify caspase-3 activity, Annexin V positivity, and cytochrome c release. Decision rule: If Bcl-2 overexpression significantly suppresses MOMP and reduces caspase-3 activation and apoptosis (for example, by $\\geq 50\\%$, with $p<0.05$) while caspase-8 inhibition abolishes apoptosis in both vector and Bcl-2 cells, classify as type II. If Bcl-2 overexpression reduces MOMP but does not significantly reduce caspase-3 activation or apoptosis, yet caspase-8 inhibition abolishes apoptosis, classify as type I.**\n\nThis option describes the exact experimental design and decision logic derived from first principles. It correctly identifies that the key differentiator is the sensitivity to Bcl-2 overexpression. It correctly states that Bcl-2 overexpression will significantly inhibit apoptosis in type II cells. It correctly notes that in type I cells, Bcl-2 will not significantly block the final apoptotic outcome. It also correctly includes the critical control that caspase-8 anhibition must block apoptosis in all contexts. The use of multiple robust readouts enhances the quality of the experiment. The parenthetical note in the type I rule (\"reduces MOMP but does not significantly reduce caspase-3 activation\") correctly allows for the possibility that some minor level of MOMP might occur in type I cells but is not required for the main apoptotic execution, which is consistent with some literature. This option is logical and scientifically sound.\n\n**Verdict: Correct**\n\n**B. Treat vector-only cells with a caspase-8 inhibitor at a submaximal ligand dose and classify as type I if the inhibitor produces near-complete blockade of apoptosis (for example, $\\geq 80\\%$ reduction) and as type II if the inhibitor produces only partial blockade (for example, $\\leq 40\\%$ reduction), because type II apoptosis is less dependent on caspase-8.**\n\nThis option is fundamentally flawed. The premise \"type II apoptosis is less dependent on caspase-8\" is incorrect. Both type I and type II extrinsic apoptosis pathways are absolutely dependent on the catalytic activity of caspase-8 as the initiator caspase. In both cases, caspase-8 lies at the apex of the cascade, directly downstream of the DISC. Inhibition of caspase-8 will therefore block the initiation of apoptosis in both cell types. The difference between type I and type II cells is the *amount* of active caspase-8 required to trigger downstream events, not the *dependency* on caspase-8 itself. This strategy would fail to distinguish the two types.\n\n**Verdict: Incorrect**\n\n**C. Overexpress Bcl-2 and measure caspase-8 enzymatic activity at $2$ hours post-stimulation. If Bcl-2 reduces caspase-8 activity by $\\geq 50\\%$, classify as type II, because Bcl-2 is upstream of caspase-8 in type II cells but not in type I cells.**\n\nThis option contains a critical error of fact. The foundational facts explicitly state that \"Bcl-2 localizes to mitochondria and blocks MOMP; Bcl-2 does not inhibit DISC formation or caspase-8 activation.\" Therefore, Bcl-2 is downstream of caspase-8 activation in both type I and type II pathways. It acts at the mitochondrial level to block the amplification loop required in type II cells. It cannot possibly affect the activity of caspase-8 which is generated upstream at the DISC. The premise of this option is in direct contradiction with the provided biological facts.\n\n**Verdict: Incorrect**\n\n**D. Perform the $2 \\times 2$ matrix with vector/Bcl-2 and $\\pm$ caspase-8 inhibitor, but use only caspase-3 activity as the readout. Decision rule: Classify as type I only if caspase-8 inhibition fails to block caspase-3 activation in Bcl-2 overexpressing cells, because type I cells have caspase-8-independent executioner activation, and as type II if caspase-8 inhibition blocks caspase-3 in both vector and Bcl-2 cells.**\n\nThis option's decision rule is based on a completely false premise. The statement \"type I cells have caspase-8-independent executioner activation\" is incorrect in the context of extrinsic apoptosis. The very definition of extrinsic apoptosis (both types) involves initiation by death receptors and caspase-8. Therefore, inhibition of caspase-8 *must* block subsequent caspase-3 activation in type I cells, just as it does in type II cells. The proposed decision rule—looking for a case where caspase-8 inhibition *fails* to block apoptosis—is designed to detect a phenomenon that does not occur in either pathway as defined.\n\n**Verdict: Incorrect**", "answer": "$$\\boxed{A}$$", "id": "2932745"}, {"introduction": "The decision to undergo apoptosis often hinges on a delicate balance of pro- and anti-apoptotic proteins of the BCL-2 family. This problem moves from the conceptual to the quantitative, asking you to build a biophysical model of this critical control point based on the law of mass action. By calculating the concentration of free BAX available to trigger mitochondrial permeabilization in the presence of its inhibitors and a competing peptide, you will gain hands-on experience in modeling the competitive binding equilibria that lie at the heart of cell fate decisions [@problem_id:2777000].", "problem": "In the intrinsic apoptosis pathway, the BCL-2-associated X protein (BAX) is sequestered by anti-apoptotic proteins such as B-cell lymphoma 2 (BCL-2) and induced myeloid leukemia cell differentiation protein (MCL-1) through 1:1 binding. A BCL-2 homology 3 (BH3) peptide can competitively bind to BCL-2 and MCL-1 and thereby displace BAX. Assume the following scientifically standard bases: (i) binding is reversible, 1:1, and at thermodynamic equilibrium; (ii) the law of mass action holds; (iii) total concentrations of each protein are conserved.\n\nConsider a well-mixed solution at equilibrium containing total concentrations $[{\\mathrm{BAX}}]_{T}$, $[{\\mathrm{BCL\\text{-}2}}]_{T}$, $[{\\mathrm{MCL\\text{-}1}}]_{T}$, and $[{\\mathrm{BH3}}]_{T}$, with dissociation constants $K_{d}^{X\\!C}$ for BAX:BCL-2, $K_{d}^{X\\!M}$ for BAX:MCL-1, $K_{d}^{H\\!C}$ for BH3:BCL-2, and $K_{d}^{H\\!M}$ for BH3:MCL-1. Write the mass-action relations and conservation laws for all species and use them to compute the equilibrium fraction of free BAX available to oligomerize, defined as $f \\equiv [{\\mathrm{BAX}}]_{\\mathrm{free}}/[{\\mathrm{BAX}}]_{T}$, under the parameter set:\n- $[{\\mathrm{BAX}}]_{T} = 40~\\mathrm{nM}$,\n- $[{\\mathrm{BCL\\text{-}2}}]_{T} = 20~\\mathrm{nM}$,\n- $[{\\mathrm{MCL\\text{-}1}}]_{T} = 25~\\mathrm{nM}$,\n- $[{\\mathrm{BH3}}]_{T} = 50~\\mathrm{nM}$,\n- $K_{d}^{X\\!C} = 20~\\mathrm{nM}$,\n- $K_{d}^{X\\!M} = 5~\\mathrm{nM}$,\n- $K_{d}^{H\\!C} = 0.5~\\mathrm{nM}$,\n- $K_{d}^{H\\!M} = 5000~\\mathrm{nM}$.\n\nAssume that each anti-apoptotic protein (BCL-2 or MCL-1) has a single binding groove that can be occupied by either one BAX or one BH3 peptide, but not both simultaneously, and that BH3 does not directly bind BAX. Start from the law of mass action and conservation of mass to derive the necessary relations. Then determine $f$ at equilibrium. Round your final numerical result to four significant figures and express it as a unitless decimal fraction.", "solution": "The fundamental bases are (i) the law of mass action for reversible 1:1 binding and (ii) conservation of mass for each protein. Let $b \\equiv [{\\mathrm{BAX}}]_{\\mathrm{free}}$, $c \\equiv [{\\mathrm{BCL\\text{-}2}}]_{\\mathrm{free}}$, $m \\equiv [{\\mathrm{MCL\\text{-}1}}]_{\\mathrm{free}}$, and $h \\equiv [{\\mathrm{BH3}}]_{\\mathrm{free}}$. Denote the complexes as $X_{C} \\equiv [\\mathrm{BAX\\!:\\!BCL\\text{-}2}]$, $H_{C} \\equiv [\\mathrm{BH3\\!:\\!BCL\\text{-}2}]$, $X_{M} \\equiv [\\mathrm{BAX\\!:\\!MCL\\text{-}1}]$, and $H_{M} \\equiv [\\mathrm{BH3\\!:\\!MCL\\text{-}1}]$.\n\nBy the law of mass action for dissociation constants,\n$$\nK_{d}^{X\\!C} \\;=\\; \\frac{b\\,c}{X_{C}},\\qquad\nK_{d}^{H\\!C} \\;=\\; \\frac{h\\,c}{H_{C}},\\qquad\nK_{d}^{X\\!M} \\;=\\; \\frac{b\\,m}{X_{M}},\\qquad\nK_{d}^{H\\!M} \\;=\\; \\frac{h\\,m}{H_{M}}.\n$$\n\nConservation of mass for each protein gives\n$$\n[{\\mathrm{BAX}}]_{T} \\;=\\; b + X_{C} + X_{M},\n\\qquad\n[{\\mathrm{BCL\\text{-}2}}]_{T} \\;=\\; c + X_{C} + H_{C},\n$$\n$$\n[{\\mathrm{MCL\\text{-}1}}]_{T} \\;=\\; m + X_{M} + H_{M},\n\\qquad\n[{\\mathrm{BH3}}]_{T} \\;=\\; h + H_{C} + H_{M}.\n$$\n\nSolve for free anti-apoptotic concentrations in terms of $b$ and $h$ by eliminating $X_{C},H_{C}$ and $X_{M},H_{M}$. For BCL-2,\n$$\nX_{C} \\;=\\; \\frac{b\\,c}{K_{d}^{X\\!C}},\n\\qquad\nH_{C} \\;=\\; \\frac{h\\,c}{K_{d}^{H\\!C}},\n\\qquad\n[{\\mathrm{BCL\\text{-}2}}]_{T} \\;=\\; c\\!\\left(1 + \\frac{b}{K_{d}^{X\\!C}} + \\frac{h}{K_{d}^{H\\!C}}\\right),\n$$\nhence\n$$\nc \\;=\\; \\frac{[{\\mathrm{BCL\\text{-}2}}]_{T}}{1 + \\frac{b}{K_{d}^{X\\!C}} + \\frac{h}{K_{d}^{H\\!C}}}.\n$$\nSimilarly, for MCL-1,\n$$\nm \\;=\\; \\frac{[{\\mathrm{MCL\\text{-}1}}]_{T}}{1 + \\frac{b}{K_{d}^{X\\!M}} + \\frac{h}{K_{d}^{H\\!M}}}.\n$$\n\nSubstitute $X_{C} = \\frac{b\\,c}{K_{d}^{X\\!C}}$ and $X_{M} = \\frac{b\\,m}{K_{d}^{X\\!M}}$ into the BAX balance, and $H_{C} = \\frac{h\\,c}{K_{d}^{H\\!C}}$, $H_{M} = \\frac{h\\,m}{K_{d}^{H\\!M}}$ into the BH3 balance to obtain two coupled equations in $b$ and $h$:\n$$\n[{\\mathrm{BAX}}]_{T} \\;=\\; b\\!\\left(1 + \\frac{c}{K_{d}^{X\\!C}} + \\frac{m}{K_{d}^{X\\!M}}\\right),\n\\qquad\n[{\\mathrm{BH3}}]_{T} \\;=\\; h\\!\\left(1 + \\frac{c}{K_{d}^{H\\!C}} + \\frac{m}{K_{d}^{H\\!M}}\\right),\n$$\nwith $c$ and $m$ as functions of $b,h$ given above.\n\nWith the provided parameters, we first assess limiting regimes to simplify. The BH3 peptide is highly affine to BCL-2 and present in excess relative to $[{\\mathrm{BCL\\text{-}2}}]_{T}$: $K_{d}^{H\\!C} = 0.5~\\mathrm{nM}$ and $[{\\mathrm{BH3}}]_{T} = 50~\\mathrm{nM}$ versus $[{\\mathrm{BCL\\text{-}2}}]_{T} = 20~\\mathrm{nM}$. In contrast, BH3 binds MCL-1 extremely weakly: $K_{d}^{H\\!M} = 5000~\\mathrm{nM}$. Anticipating $h$ on the order of tens of $\\mathrm{nM}$, the dimensionless occupancies scale as\n$$\n\\frac{h}{K_{d}^{H\\!C}} \\;\\gg\\; \\frac{b}{K_{d}^{X\\!C}} \\quad\\Rightarrow\\quad \\text{BCL-2 is essentially saturated by BH3, } X_{C} \\approx 0,\n$$\n$$\n\\frac{h}{K_{d}^{H\\!M}} \\;\\ll\\; 1 \\quad\\Rightarrow\\quad \\text{BH3 negligibly occupies MCL-1, } H_{M} \\approx 0.\n$$\nThese parameter inequalities reduce the system to a single competitive interaction between BAX and MCL-1, with BCL-2 effectively unavailable to BAX and BH3 effectively noncompetitive on MCL-1. In this reduced, exact limit, the remaining balances are\n$$\n[{\\mathrm{BAX}}]_{T} \\;=\\; b + X_{M}, \\qquad [{\\mathrm{MCL\\text{-}1}}]_{T} \\;=\\; m + X_{M}, \\qquad K_{d}^{X\\!M} \\;=\\; \\frac{b\\,m}{X_{M}}.\n$$\nEliminate $b = [{\\mathrm{BAX}}]_{T} - X_{M}$ and $m = [{\\mathrm{MCL\\text{-}1}}]_{T} - X_{M}$ in the law of mass action to obtain a quadratic for $X_{M}$:\n$$\nK_{d}^{X\\!M} \\;=\\; \\frac{([{\\mathrm{BAX}}]_{T} - X_{M})([{\\mathrm{MCL\\text{-}1}}]_{T} - X_{M})}{X_{M}},\n$$\n$$\nX_{M}^{2} \\;-\\; X_{M}\\!\\left([{\\mathrm{BAX}}]_{T} + [{\\mathrm{MCL\\text{-}1}}]_{T} + K_{d}^{X\\!M}\\right) \\;+\\; [{\\mathrm{BAX}}]_{T}[{\\mathrm{MCL\\text{-}1}}]_{T} \\;=\\; 0.\n$$\nThe physically relevant root (the smaller, bounded by $\\min([{\\mathrm{BAX}}]_{T}, [{\\mathrm{MCL\\text{-}1}}]_{T})$) is\n$$\nX_{M} \\;=\\; \\frac{[{\\mathrm{BAX}}]_{T} + [{\\mathrm{MCL\\text{-}1}}]_{T} + K_{d}^{X\\!M} \\;-\\; \\sqrt{\\left([{\\mathrm{BAX}}]_{T} + [{\\mathrm{MCL\\text{-}1}}]_{T} + K_{d}^{X\\!M}\\right)^{2} - 4\\,[{\\mathrm{BAX}}]_{T}[{\\mathrm{MCL\\text{-}1}}]_{T}}}{2}.\n$$\nThen $b = [{\\mathrm{BAX}}]_{T} - X_{M}$ and the free fraction is\n$$\nf \\;=\\; \\frac{b}{[{\\mathrm{BAX}}]_{T}} \\;=\\; 1 \\;-\\; \\frac{X_{M}}{[{\\mathrm{BAX}}]_{T}}.\n$$\n\nSubstitute the given numbers for the reduced model evaluation:\n$$\n[{\\mathrm{BAX}}]_{T} = 40,\\quad [{\\mathrm{MCL\\text{-}1}}]_{T} = 25,\\quad K_{d}^{X\\!M} = 5 \\quad (\\text{all in }\\mathrm{nM}),\n$$\n$$\nX_{M} \\;=\\; \\frac{40 + 25 + 5 - \\sqrt{(40 + 25 + 5)^{2} - 4\\cdot 40 \\cdot 25}}{2}\n\\;=\\; \\frac{70 - \\sqrt{4900 - 4000}}{2}\n\\;=\\; \\frac{70 - 30}{2}\n\\;=\\; 20,\n$$\n$$\nb \\;=\\; 40 - 20 \\;=\\; 20,\\qquad f \\;=\\; \\frac{20}{40} \\;=\\; 0.5.\n$$\n\nTo confirm that the approximations introducing the reduced model incur only negligible error under the full coupled system, we evaluate the exact coupled equations numerically using the original parameters. Solving\n$$\nc \\;=\\; \\frac{20}{1 + \\frac{b}{20} + \\frac{h}{0.5}},\\qquad\nm \\;=\\; \\frac{25}{1 + \\frac{b}{5} + \\frac{h}{5000}},\n$$\n$$\n40 \\;=\\; b\\!\\left(1 + \\frac{c}{20} + \\frac{m}{5}\\right),\\qquad\n50 \\;=\\; h\\!\\left(1 + \\frac{c}{0.5} + \\frac{m}{5000}\\right),\n$$\nyields $b \\approx 19.760$ and hence\n$$\nf \\;=\\; \\frac{b}{40} \\;\\approx\\; \\frac{19.760}{40} \\;=\\; 0.494.\n$$\nUnder these conditions, $[{\\mathrm{BAX}}]$ bound to BCL-2 is tiny (on the order of $3.2\\times 10^{-1}~\\mathrm{nM}$), consistent with $K_{d}^{H\\!C} \\ll K_{d}^{X\\!C}$ and $[{\\mathrm{BH3}}]_{T} \\gg [{\\mathrm{BCL\\text{-}2}}]_{T}$, while BH3 occupancy of MCL-1 remains negligible due to $K_{d}^{H\\!M} \\gg [\\text{all}]$. Therefore, the full-equilibrium free BAX fraction is $f \\approx 0.494$.\n\nRounded to four significant figures as requested, the equilibrium fraction of free BAX is $0.4940$.", "answer": "$$\\boxed{0.4940}$$", "id": "2777000"}, {"introduction": "Once the decision to die is made, the cell is dismantled by a cascade of proteases, with caspase-3 acting as a primary executioner. This practice focuses on the terminal phase of apoptosis by applying the principles of enzyme kinetics to caspase-3 activity. You will derive the Michaelis-Menten equation from first principles and use it to calculate reaction velocities, reinforcing your understanding of how key enzymatic parameters like $k_{\\mathrm{cat}}$ and $K_M$ quantitatively describe the efficiency of this irreversible process [@problem_id:2932773].", "problem": "Caspase-3, a cysteine-aspartate protease that executes the apoptotic program, cleaves peptide substrates carrying an Asp-Glu-Val-Asp (DEVD) motif. In a chromogenic assay, the synthetic substrate DEVD-para-nitroanilide (DEVD-pNA) is used to monitor activity via release of para-nitroaniline. Consider the minimal one-intermediate enzyme mechanism under the law of mass action for caspase-3 catalysis of DEVD-pNA cleavage, where the enzyme-substrate complex forms and breaks down to product in a single catalytic step, and assume the quasi-steady-state assumption (QSSA) applies. Assume initial transient and product inhibition are negligible, substrate is in large excess relative to total enzyme, and substrate concentration is effectively constant over the initial-rate interval.\n\nStarting from these mechanistic premises and the definition of the Michaelis constant $K_{M}$ as a composite of elementary rate constants for this mechanism, derive the expression for the initial velocity $v_{0}$ as a function of $k_{\\mathrm{cat}}$, $K_{M}$, the total active-site concentration $[E]_{0}$, and the substrate concentration $[S]$. Then, using $k_{\\mathrm{cat}}=2\\,\\mathrm{s}^{-1}$, $K_{M}=10\\,\\mu\\mathrm{M}$, total active-site concentration $[E]_{0}=25\\,\\mathrm{nM}$, and initial substrate concentrations $[S]=5\\,\\mu\\mathrm{M}$, $[S]=10\\,\\mu\\mathrm{M}$, and $[S]=50\\,\\mu\\mathrm{M}$, compute the corresponding initial velocities. Express each initial velocity in $\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}$ and round each value to four significant figures.", "solution": "The problem statement is subjected to validation before any attempt at a solution.\n\n### Step 1: Extract Givens\n- **Enzyme**: Caspase-3\n- **Substrate**: DEVD-pNA (Asp-Glu-Val-Asp-para-nitroanilide)\n- **Mechanism**: Minimal one-intermediate enzyme mechanism, $E + S \\rightleftharpoons ES \\rightarrow E + P$, governed by the law of mass action.\n- **Assumptions**:\n    - Quasi-steady-state assumption (QSSA) applies to the enzyme-substrate complex $[ES]$.\n    - Initial transient is negligible.\n    - Product inhibition is negligible.\n    - Substrate is in large excess relative to total enzyme concentration.\n    - Substrate concentration $[S]$ is effectively constant over the initial-rate interval.\n- **Definitions**: The Michaelis constant $K_M$ is a composite of elementary rate constants for this mechanism.\n- **Tasks**:\n    1. Derive the expression for the initial velocity $v_0$ as a function of $k_{\\mathrm{cat}}$, $K_M$, $[E]_0$, and $[S]$.\n    2. Compute $v_0$ for given values.\n- **Data for Calculation**:\n    - $k_{\\mathrm{cat}} = 2\\,\\mathrm{s}^{-1}$\n    - $K_M = 10\\,\\mu\\mathrm{M}$\n    - Total active-site concentration $[E]_0 = 25\\,\\mathrm{nM}$\n    - Initial substrate concentrations $[S]$: $5\\,\\mu\\mathrm{M}$, $10\\,\\mu\\mathrm{M}$, $50\\,\\mu\\mathrm{M}$.\n- **Output Format**: Initial velocities in $\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}$, rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded. The mechanism described is the standard Michaelis-Menten model for enzyme kinetics. Caspase-3 and its DEVD substrate are core components of the apoptosis pathway, a fundamental topic in molecular and cell biology. The use of the quasi-steady-state assumption (QSSA) is a standard and rigorous method for deriving the Michaelis-Menten equation. The problem is well-posed, providing all necessary constants, conditions, and assumptions required to derive the velocity equation and perform the subsequent calculations. The provided numerical values are physically plausible for an enzymatic reaction. For instance, the condition $[S] \\gg [E]_0$ is met, as the lowest substrate concentration is $5\\,\\mu\\mathrm{M} = 5000\\,\\mathrm{nM}$, which is much greater than $[E]_0 = 25\\,\\mathrm{nM}$. The problem is objective, quantifiable, and free of any logical contradictions or ambiguities.\n\n### Step 3: Verdict and Action\nThe problem is valid. A solution will be provided.\n\nThe minimal one-intermediate enzyme mechanism is represented by the following reaction scheme:\n$$ E + S \\underset{k_{-1}}{\\stackrel{k_1}{\\rightleftharpoons}} ES \\stackrel{k_2}{\\rightarrow} E + P $$\nwhere $E$ is the enzyme (caspase-3), $S$ is the substrate (DEVD-pNA), $ES$ is the enzyme-substrate complex, and $P$ is the product (para-nitroaniline and the cleaved peptide). The elementary rate constants are $k_1$, $k_{-1}$, and $k_2$.\n\nThe rate of formation of the product, which defines the reaction velocity $v$, is given by:\n$$ v = \\frac{d[P]}{dt} = k_2 [ES] $$\nThe rate of change of the concentration of the enzyme-substrate complex, $[ES]$, is determined by its formation and breakdown:\n$$ \\frac{d[ES]}{dt} = k_1 [E][S] - k_{-1}[ES] - k_2[ES] $$\nThe problem states that the quasi-steady-state assumption (QSSA) applies. This assumes that after a brief initial transient, the concentration of the intermediate complex $[ES]$ remains approximately constant, i.e., $\\frac{d[ES]}{dt} \\approx 0$. Applying this assumption:\n$$ k_1 [E][S] - (k_{-1} + k_2)[ES] = 0 $$\n$$ k_1 [E][S] = (k_{-1} + k_2)[ES] $$\nThe total enzyme concentration, $[E]_0$, is constant and is the sum of the free enzyme $[E]$ and the enzyme bound in the complex $[ES]$:\n$$ [E]_0 = [E] + [ES] $$\nThus, the concentration of free enzyme is $[E] = [E]_0 - [ES]$. Substituting this into the steady-state equation:\n$$ k_1 ([E]_0 - [ES])[S] = (k_{-1} + k_2)[ES] $$\nExpanding the left side:\n$$ k_1 [E]_0 [S] - k_1 [ES][S] = (k_{-1} + k_2)[ES] $$\nRearranging to solve for $[ES]$:\n$$ k_1 [E]_0 [S] = (k_{-1} + k_2)[ES] + k_1 [ES][S] $$\n$$ k_1 [E]_0 [S] = (k_{-1} + k_2 + k_1 [S])[ES] $$\n$$ [ES] = \\frac{k_1 [E]_0 [S]}{k_{-1} + k_2 + k_1 [S]} $$\nTo introduce the Michaelis constant $K_M$, we divide the numerator and the denominator by $k_1$:\n$$ [ES] = \\frac{[E]_0 [S]}{\\frac{k_{-1} + k_2}{k_1} + [S]} $$\nAs prescribed by the problem statement, the Michaelis constant $K_M$ for this mechanism is defined as the composite of elementary rate constants:\n$$ K_M = \\frac{k_{-1} + k_2}{k_1} $$\nSubstituting this definition, we obtain the expression for the steady-state concentration of the $ES$ complex:\n$$ [ES] = \\frac{[E]_0 [S]}{K_M + [S]} $$\nThe initial velocity $v_0$ is the velocity at time $t=0$, under the assumption that product concentration is negligible. The catalytic constant, $k_{\\mathrm{cat}}$, represents the turnover number of the enzyme. For this minimal mechanism, $k_{\\mathrm{cat}}$ is equivalent to the rate constant for the catalytic step, $k_2$.\n$$ v_0 = k_{\\mathrm{cat}} [ES] $$\nSubstituting the expression for $[ES]$ gives the final derived form for the initial velocity, known as the Michaelis-Menten equation:\n$$ v_0 = k_{\\mathrm{cat}} \\frac{[E]_0 [S]}{K_M + [S]} $$\nThis is the required expression.\n\nNext, we compute the initial velocities for the given parameters. The parameters are:\n$k_{\\mathrm{cat}} = 2\\,\\mathrm{s}^{-1}$\n$K_M = 10\\,\\mu\\mathrm{M}$\n$[E]_0 = 25\\,\\mathrm{nM}$\n\nBefore calculation, units must be consistent. The desired unit for $v_0$ is $\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}$. To achieve this, all concentrations must be in $\\mu\\mathrm{M}$. The total enzyme concentration is given in $\\mathrm{nM}$:\n$$ [E]_0 = 25\\,\\mathrm{nM} = 25 \\times 10^{-3}\\,\\mu\\mathrm{M} = 0.025\\,\\mu\\mathrm{M} $$\nNow we can compute $v_0$ for each substrate concentration.\n\nCase 1: $[S] = 5\\,\\mu\\mathrm{M}$\n$$ v_0 = \\frac{(2\\,\\mathrm{s}^{-1}) (0.025\\,\\mu\\mathrm{M}) (5\\,\\mu\\mathrm{M})}{10\\,\\mu\\mathrm{M} + 5\\,\\mu\\mathrm{M}} = \\frac{0.25}{15}\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1} \\approx 0.016666...\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1} $$\nRounding to four significant figures gives $0.01667\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}$.\n\nCase 2: $[S] = 10\\,\\mu\\mathrm{M}$\nIn this case, $[S] = K_M$. The velocity should be half of the maximum velocity, $V_{\\mathrm{max}}$.\n$V_{\\mathrm{max}} = k_{\\mathrm{cat}}[E]_0 = (2\\,\\mathrm{s}^{-1})(0.025\\,\\mu\\mathrm{M}) = 0.05\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}$.\nTherefore, $v_0 = \\frac{1}{2} V_{\\mathrm{max}} = 0.025\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}$.\nLet us verify with the full equation:\n$$ v_0 = \\frac{(2\\,\\mathrm{s}^{-1}) (0.025\\,\\mu\\mathrm{M}) (10\\,\\mu\\mathrm{M})}{10\\,\\mu\\mathrm{M} + 10\\,\\mu\\mathrm{M}} = \\frac{0.5}{20}\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1} = 0.025\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1} $$\nRounding to four significant figures requires expressing this as $0.02500\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}$.\n\nCase 3: $[S] = 50\\,\\mu\\mathrm{M}$\n$$ v_0 = \\frac{(2\\,\\mathrm{s}^{-1}) (0.025\\,\\mu\\mathrm{M}) (50\\,\\mu\\mathrm{M})}{10\\,\\mu\\mathrm{M} + 50\\,\\mu\\mathrm{M}} = \\frac{2.5}{60}\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1} \\approx 0.041666...\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1} $$\nRounding to four significant figures gives $0.04167\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}$.\n\nThe three computed initial velocities are $0.01667\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}$, $0.02500\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}$, and $0.04167\\,\\mu\\mathrm{M}\\,\\mathrm{s}^{-1}$.", "answer": "$$\n\\boxed{\\begin{pmatrix} 0.01667 & 0.02500 & 0.04167 \\end{pmatrix}}\n$$", "id": "2932773"}]}